Adrestia

Alia Therapeutics

The company develops gene editing medicines for patients with genetic diseases.

Immitra Bio

This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.

EdiTy Therapeutics

This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.

Scenic Biotech

This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.

Anjarium BioSciences

This company develops non-viral gene therapies and synthetic DNA vectors for patients with genetic diseases and life sciences researchers.

Epitome Therapeutics

This biotechnology firm develops an epigenome editing platform for programmable gene expression to treat patients with rare genetic and metabolic disorders.

Sidera

This company develops small molecule medicines for patients with metabolic, inflammatory and kidney diseases using human genetic research findings.

Stridebio

This company develops engineered viral vectors and gene therapies for patients with rare genetic diseases.